vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and RXO, Inc. (RXO). Click either name above to swap in a different company.
RXO, Inc. is the larger business by last-quarter revenue ($1.5B vs $1.1B, roughly 1.3× Elanco Animal Health Inc). RXO, Inc. runs the higher net margin — -3.1% vs -24.1%, a 21.0% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs -11.9%). Elanco Animal Health Inc produced more free cash flow last quarter ($46.0M vs $-9.0M). Over the past eight quarters, RXO, Inc.'s revenue compounded faster (26.8% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
RXO, Inc. is a leading transportation and logistics solutions provider headquartered in the United States. Its core service portfolio includes freight brokerage, last-mile delivery for heavy and bulky goods, managed transportation services, and end-to-end supply chain optimization support, primarily catering to clients across the North American manufacturing, retail, and e-commerce segments.
ELAN vs RXO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.5B |
| Net Profit | $-276.0M | $-46.0M |
| Gross Margin | 51.5% | — |
| Operating Margin | -22.6% | -2.9% |
| Net Margin | -24.1% | -3.1% |
| Revenue YoY | 12.2% | -11.9% |
| Net Profit YoY | -3350.0% | -84.0% |
| EPS (diluted) | $-0.55 | $-0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.2B | $1.4B | ||
| Q4 24 | $1.0B | $1.7B | ||
| Q3 24 | $1.0B | $1.0B | ||
| Q2 24 | $1.2B | $930.0M | ||
| Q1 24 | $1.2B | $913.0M |
| Q4 25 | $-276.0M | $-46.0M | ||
| Q3 25 | $-34.0M | $-14.0M | ||
| Q2 25 | $11.0M | $-9.0M | ||
| Q1 25 | $67.0M | $-31.0M | ||
| Q4 24 | $-8.0M | $-25.0M | ||
| Q3 24 | $364.0M | $-243.0M | ||
| Q2 24 | $-50.0M | $-7.0M | ||
| Q1 24 | $32.0M | $-15.0M |
| Q4 25 | 51.5% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 52.2% | — | ||
| Q2 24 | 58.2% | — | ||
| Q1 24 | 57.3% | — |
| Q4 25 | -22.6% | -2.9% | ||
| Q3 25 | -4.4% | -0.5% | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 5.0% | -2.1% | ||
| Q4 24 | -5.0% | -1.4% | ||
| Q3 24 | 54.3% | -1.9% | ||
| Q2 24 | -2.7% | — | ||
| Q1 24 | 1.0% | -1.3% |
| Q4 25 | -24.1% | -3.1% | ||
| Q3 25 | -3.0% | -1.0% | ||
| Q2 25 | 0.9% | -0.6% | ||
| Q1 25 | 5.6% | -2.2% | ||
| Q4 24 | -0.8% | -1.5% | ||
| Q3 24 | 35.3% | -23.4% | ||
| Q2 24 | -4.2% | -0.8% | ||
| Q1 24 | 2.7% | -1.6% |
| Q4 25 | $-0.55 | $-0.28 | ||
| Q3 25 | $-0.07 | $-0.08 | ||
| Q2 25 | $0.02 | $-0.05 | ||
| Q1 25 | $0.13 | $-0.18 | ||
| Q4 24 | $-0.01 | $-0.17 | ||
| Q3 24 | $0.73 | $-1.81 | ||
| Q2 24 | $-0.10 | $-0.06 | ||
| Q1 24 | $0.06 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $17.0M |
| Total DebtLower is stronger | $3.9B | $387.0M |
| Stockholders' EquityBook value | $6.5B | $1.5B |
| Total Assets | $13.4B | $3.3B |
| Debt / EquityLower = less leverage | 0.60× | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $17.0M | ||
| Q3 25 | $505.0M | $25.0M | ||
| Q2 25 | $539.0M | $18.0M | ||
| Q1 25 | $487.0M | $16.0M | ||
| Q4 24 | $468.0M | $35.0M | ||
| Q3 24 | $490.0M | $55.0M | ||
| Q2 24 | $416.0M | $7.0M | ||
| Q1 24 | $345.0M | $7.0M |
| Q4 25 | $3.9B | $387.0M | ||
| Q3 25 | $4.0B | $387.0M | ||
| Q2 25 | $4.1B | $387.0M | ||
| Q1 25 | $4.4B | $387.0M | ||
| Q4 24 | $4.3B | $351.0M | ||
| Q3 24 | $4.4B | $352.0M | ||
| Q2 24 | $5.7B | $370.0M | ||
| Q1 24 | $5.8B | $351.0M |
| Q4 25 | $6.5B | $1.5B | ||
| Q3 25 | $6.7B | $1.6B | ||
| Q2 25 | $6.8B | $1.6B | ||
| Q1 25 | $6.4B | $1.6B | ||
| Q4 24 | $6.1B | $1.6B | ||
| Q3 24 | $6.5B | $1.7B | ||
| Q2 24 | $5.9B | $579.0M | ||
| Q1 24 | $6.1B | $582.0M |
| Q4 25 | $13.4B | $3.3B | ||
| Q3 25 | $13.6B | $3.2B | ||
| Q2 25 | $13.7B | $3.2B | ||
| Q1 25 | $12.9B | $3.3B | ||
| Q4 24 | $12.6B | $3.4B | ||
| Q3 24 | $13.3B | $3.4B | ||
| Q2 24 | $13.8B | $1.8B | ||
| Q1 24 | $14.0B | $1.8B |
| Q4 25 | 0.60× | 0.25× | ||
| Q3 25 | 0.59× | 0.24× | ||
| Q2 25 | 0.61× | 0.24× | ||
| Q1 25 | 0.69× | 0.24× | ||
| Q4 24 | 0.70× | 0.22× | ||
| Q3 24 | 0.67× | 0.21× | ||
| Q2 24 | 0.96× | 0.64× | ||
| Q1 24 | 0.95× | 0.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $7.0M |
| Free Cash FlowOCF − Capex | $46.0M | $-9.0M |
| FCF MarginFCF / Revenue | 4.0% | -0.6% |
| Capex IntensityCapex / Revenue | 5.4% | 1.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $-8.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $7.0M | ||
| Q3 25 | $219.0M | $23.0M | ||
| Q2 25 | $237.0M | $23.0M | ||
| Q1 25 | $-4.0M | $-2.0M | ||
| Q4 24 | $177.0M | $-7.0M | ||
| Q3 24 | $162.0M | $-7.0M | ||
| Q2 24 | $200.0M | $-5.0M | ||
| Q1 24 | $2.0M | $7.0M |
| Q4 25 | $46.0M | $-9.0M | ||
| Q3 25 | $127.0M | $9.0M | ||
| Q2 25 | $180.0M | $9.0M | ||
| Q1 25 | $-69.0M | $-17.0M | ||
| Q4 24 | $130.0M | $-19.0M | ||
| Q3 24 | $120.0M | $-18.0M | ||
| Q2 24 | $166.0M | $-16.0M | ||
| Q1 24 | $-22.0M | $-4.0M |
| Q4 25 | 4.0% | -0.6% | ||
| Q3 25 | 11.2% | 0.6% | ||
| Q2 25 | 14.5% | 0.6% | ||
| Q1 25 | -5.8% | -1.2% | ||
| Q4 24 | 12.7% | -1.1% | ||
| Q3 24 | 11.7% | -1.7% | ||
| Q2 24 | 14.0% | -1.7% | ||
| Q1 24 | -1.8% | -0.4% |
| Q4 25 | 5.4% | 1.1% | ||
| Q3 25 | 8.1% | 1.0% | ||
| Q2 25 | 4.6% | 1.0% | ||
| Q1 25 | 5.4% | 1.0% | ||
| Q4 24 | 4.6% | 0.7% | ||
| Q3 24 | 4.1% | 1.1% | ||
| Q2 24 | 2.9% | 1.2% | ||
| Q1 24 | 2.0% | 1.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 21.55× | — | ||
| Q1 25 | -0.06× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
